½ÃÀ庸°í¼­
»óǰÄÚµå
1645222

¼¼°èÀÇ HbA1c(´çÈ­Ç÷»ö¼Ò) ½ÇÇè½Ç °Ë»ç ½ÃÀå : ¼ºÀå, Àü¸Á, °æÀï ºÐ¼®(2025-2033³â)

HbA1c Laboratory Testing Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Acute Market Reports | ÆäÀÌÁö Á¤º¸: ¿µ¹® 176 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÇ·á Áø´ÜÀÇ ¿µ¿ª¿¡¼­ ´çÈ­Ç÷»ö¼Ò ½ÇÇè½Ç °Ë»ç´Â ƯÈ÷ ´ç´¢º´ °ü¸® ¹× ¸ð´ÏÅ͸µÀÇ ¸Æ¶ô¿¡¼­ ÁßÃßÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù. HbA1c °Ë»ç´Â 3°³¿ù µ¿¾ÈÀÇ Æò±Õ Ç÷´ç ¼öÄ¡¸¦ Á¦°øÇÏ¿© ÀÓ»óÀÇ¿¡°Ô ȯÀÚÀÇ Ç÷´ç Á¶Àý¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ´çÈ­Ç÷»ö¼Ò ½ÇÇè½Ç °Ë»ç ½ÃÀåÀº 2025³âºÎÅÍ 2033³â±îÁö 5.5%ÀÇ ¿¬Æò±Õ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ¼¼°èÀÇ °Ç°­ Æ®·»µåºÎÅÍ ±â¼ú ¹ßÀü¿¡ µû¸¥ ºü¸¥ ±â¼ú ¹ßÀü¿¡ À̸£±â±îÁö ¼ö¸¹Àº ¿äÀο¡ ÀÇÇØ ¿µÇâÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃËÁø¿äÀÎ : ¼¼°èÀÇ ´ç´¢º´ À¯º´·ü »ó½Â

´ç´¢º´ÀÌ Àü ¼¼°èÀûÀ¸·Î ½É°¢ÇÑ °øÁß º¸°Ç ¹®Á¦·Î ´ëµÎµÇ¸é¼­ ´çÈ­Ç÷»ö¼Ò(HbA1c) ½ÇÇè½Ç °Ë»ç¸¦ ºñ·ÔÇÑ È¿°úÀûÀÎ ¸ð´ÏÅ͸µ µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ ´«¿¡ ¶ç°Ô ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°èº¸°Ç±â±¸(WHO)´Â Áö³­ 10³â°£ Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´ ¹ßº´·üÀÌ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ´Ù°í º¸°íÇÏ¿© ÀÌ °Ç°­ ¹®Á¦°¡ ¾ó¸¶³ª ½É°¢ÇÏ°í ½Ã±ÞÇÑÁö¸¦ º¸¿©ÁÝ´Ï´Ù. ÀÌ¿¡ µû¶ó ´çÈ­Ç÷»ö¼Ò °Ë»ç´Â ÀÇ·á ÇöÀå¿¡¼­ ¾ø¾î¼­´Â ¾È µÉ Çʼö ¿ä¼Ò°¡ µÇ¾ú½À´Ï´Ù. Á¤±âÀûÀÎ ´çÈ­Ç÷»ö¼Ò °Ë»ç¸¦ ÅëÇØ Àû½Ã¿¡ °³ÀÔÇÏ°í ¾à¹° ¿ä¹ýÀ» Á¶Á¤ÇÒ ¼ö ÀÖÀ¸¸ç ½Å°æº´Áõ, ½ÅÀ庴Áõ, ¸Á¸·º´Áõ°ú °°Àº ´ç´¢º´ °ü·Ã ÇÕº´ÁõÀ» ¿¹¹æÇÏ¿© ȯÀÚÀÇ Ä¡·á °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

±âȸ : Áø´Ü¿¡¼­ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕ

ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML) ¿µ¿ªÀÇ ±â¼ú ¹ßÀüÀ¸·Î ´çÈ­Ç÷»ö¼Ò °Ë»ç ½ÃÀå¿¡ »õ·Î¿î ÁöÆòÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. HbA1c °á°ú ¹× ±âŸ ȯÀÚ µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ´ç´¢º´ ÁøÇà ¹× °ü·Ã ÇÕº´ÁõÀ» ¿¹ÃøÇϱâ À§ÇØ AI ¾Ë°í¸®ÁòÀ» Ȱ¿ëÇÏ´Â °Í¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿©·¯ ÀÇ·á ±â¼ú ½ºÅ¸Æ®¾÷°ú ±âÁ¸ Áø´Ü ¿¬±¸¼Ò´Â AI ±â¹Ý ¿¹Ãø ºÐ¼®À» ÅëÇÕÇÏ¿© HbA1c °Ë»ç °á°ú¿¡¼­ º¸´Ù ½ÇÇà °¡´ÉÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ´Â ¹æ¹ýÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â °Ë»çÀÇ ÀÓ»óÀû À¯¿ë¼ºÀ» ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó ¿¹¹æÀû Ä¡·áÀÇ ÇÑ ÃþÀ» Ãß°¡ÇÏ¿© ÀÓ»óÀÇÀÇ »çÀü ¿¹¹æÀû ȯÀÚ °ü¸®¸¦ Áö¿øÇÕ´Ï´Ù.

¾ïÁ¦¿äÀÎ : Àú¼Òµæ Áö¿ª¿¡¼­ ³ôÀº °Ë»ç ºñ¿ë°ú Á¦ÇÑµÈ Á¢±Ù¼º

´çÈ­Ç÷»ö¼Ò °Ë»çÀÇ Á߿伺Àº ºÎÀÎÇÒ ¼ö ¾øÁö¸¸, ¸¹Àº »ç¶÷µé¿¡°Ô´Â ºñ¿ëÀÌ »ó´çÇÑ À庮À¸·Î ³²¾Æ ÀÖ½À´Ï´Ù. ÀϺΠÁö¿ª, ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â Á¤±âÀûÀÎ ´çÈ­Ç÷»ö¼Ò °Ë»ç¿Í °ü·ÃµÈ ºñ¿ëÀÌ ¾öû³¯ ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀϺΠº¸Çè Á¤Ã¥¿¡¼­´Â ´çÈ­Ç÷»ö¼Ò °Ë»ç¸¦ º¸ÀåÇÏÁö ¾Ê±â ¶§¹®¿¡ ȯÀÚÀÇ º»ÀÎ ºÎ´ã±ÝÀÌ ´õ ´Ã¾î³³´Ï´Ù. ¶ÇÇÑ °í±Þ ½ÇÇè½Ç°ú ¼÷·ÃµÈ ±â¼úÀÚ µî Çʼö ÀÎÇÁ¶ó°¡ º¸ÆíÀûÀ¸·Î Á¦°øµÇÁö ¾Ê¾Æ °Ë»ç Á¢±Ù¼ºÀÌ ´õ¿í Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ °ÝÂ÷´Â ¼±Áø±¹°ú °³¹ßµµ»ó±¹ °£ÀÇ ´ç´¢º´ Ä¡·á Á¢±Ù¼ºÀÇ ±Ø¸íÇÑ ´ëÁ¶¸¦ °­Á¶ÇÑ ±¹Á¦ ´ç´¢º´ ¿¬¸ÍÀÇ º¸°í¼­¿¡¼­ ºÐ¸íÇÏ°Ô µå·¯³µ½À´Ï´Ù.

°úÁ¦ : ÆíÂ÷¿Í Ç¥ÁØÈ­¿¡ ´ëÇÑ ¿ì·Á

´çÈ­Ç÷»ö¼Ò °Ë»ç ºÐ¾ß¿¡¼­ °¡Àå ½Ã±ÞÇÑ °úÁ¦ Áß Çϳª´Â °Ë»ç °á°úÀÇ ÀáÀçÀû º¯µ¿¼ºÀÔ´Ï´Ù. °Ë»ç½Ç¸¶´Ù ´Ù¾çÇÑ °Ë»ç ¹æ¹ý·ÐÀ» »ç¿ëÇϱ⠶§¹®¿¡ °á°ú¿¡ ¾à°£ÀÇ Â÷À̰¡ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. À̴ ƯÈ÷ ȯÀÚ°¡ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¸¦ ¹Ù²Ù°Å³ª ÀÓ»óÀǰ¡ ¿©·¯ °Ë»ç½ÇÀÇ °á°ú¿¡ ÀÇÁ¸ÇÒ ¶§ ¹®Á¦°¡ µË´Ï´Ù. ¹Ì±¹´ç´¢º´ÇÐȸ´Â ÀÌÀü¿¡ ´çÈ­Ç÷»ö¼Ò °Ë»ç Ç¥ÁØÈ­¿¡ ´ëÇÑ ¿ì·Á¸¦ °­Á¶ÇÑ ¹Ù ÀÖÀ¸¸ç, ±ÕÀϼº°ú ½Å·Ú¼ºÀ» º¸ÀåÇϱâ À§ÇØ Àü ¼¼°èÀûÀ¸·Î ÀϰüµÈ °Ë»ç ÇÁ·ÎÅäÄÝÀÌ ÇÊ¿äÇÏ´Ù°í °­Á¶ÇÑ ¹Ù ÀÖ½À´Ï´Ù.

±â¼úº° ºÐ¼®

2024³â ´çÈ­Ç÷»ö¼Ò °Ë»ç ½ÃÀåÀ» Áö¹èÇÏ´Â ±â¼úÀº ¿©·¯ ¹üÁÖ·Î ±¸ºÐÇÒ ¼ö ÀÖ½À´Ï´Ù. À̿ ±³È¯ °í¼º´É ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ(HPLC)´Â Á¤¹Ð¼º, ¹Ýº¹¼º, °ß°í¼º ´öºÐ¿¡ °¡Àå ³ôÀº ¼öÀÍÀ» âÃâÇÏ´Â ±â¼ú·Î ºÎ»óÇß½À´Ï´Ù. Àü ¼¼°è ÀÓ»óÀǵéÀº ´çÈ­Ç÷»ö¼Ò ¼öÄ¡ÀÇ ¹Ì¼¼ÇÑ Â÷À̵µ Á¤È®ÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖ´Â ÀÌ ±â¼úÀ» ¼±È£Çß½À´Ï´Ù. ±×·¯³ª ¸é¿ª ºÐ¼®Àº ³²¾Æ½Ã¾Æ¿Í °°ÀÌ Àα¸°¡ ¸¹Àº Áö¿ª¿¡ ÇʼöÀûÀÎ ½Å¼ÓÇÑ °Ë»ç ±â´É°ú ´ë·® °Ë»ç¸¦ À§ÇÑ È®À强 ´öºÐ¿¡ °¡Àå ³ôÀº CAGRÀ» º¸¿´½À´Ï´Ù. ºØ»ê¿° ģȭ¼º Å©·Î¸¶Åä±×·¡ÇÇ¿Í Á÷Á¢ È¿¼Ò ºÐ¼®Àº º¸±Þ·üÀº ³·¾ÒÁö¸¸ ƯÁ¤ ÀÓ»ó ½Ã³ª¸®¿À¿¡¼­ Æ´»õ ¼Ö·ç¼ÇÀ» Á¦°øÇß½À´Ï´Ù. ´Ù¸¥ ±â¼úµéÀº Ư¼öÇÑ ¿ä±¸ »çÇ×À» ÃæÁ·Çϰųª ƯÁ¤ Áø´Ü ¼±È£µµ°¡ ÀÖ´Â Áö¿ª¿¡ ¼­ºñ½º¸¦ Á¦°øÇϸ鼭 ½ÃÀåÀ» º¸¿ÏÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®

2024³â Áø´Ü ¿¬±¸¼Ò´Â ½ÃÀå ¼öÀÍÀÇ ÁÖ¿ä ±â¿©ÀÚ¿´½À´Ï´Ù. ¹æ´ëÇÑ ³×Æ®¿öÅ©, °¡¿ë¼º, ´çÈ­Ç÷»ö¼Ò °Ë»ç¿¡ ´ëÇÑ Àü¹®¼º ´öºÐ¿¡ ¸¹Àº ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ Áø´Ü ¿¬±¸¼Ò¸¦ ¿ì¼±ÀûÀ¸·Î ¼±ÅÃÇß½À´Ï´Ù. ¹Ý¸é, º´¿ø ±â¹Ý ½ÇÇè½ÇÀº »ó´çÇÑ ¼öÀÍÀ» âÃâÇϰí ÀÖÁö¸¸ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÀÔ¿ø ÁßÀÎ ´ç´¢º´ ȯÀÚÀÇ Áõ°¡¿Í º´¿ø ³» °Ë»ç ½Ã¼³ÀÇ ÆíÀǼºÀ¸·Î ÀÎÇØ ½Å¼ÓÇÑ °³ÀÔÀÌ °¡´ÉÇϱ⠶§¹®ÀÎ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¬±¸¼Ò¿Í °°Àº ´Ù¸¥ ±â°üµµ ƯÈ÷ ÀÓ»ó ¿¬±¸ ¹× ¿¬±¸¿Í °ü·ÃÇÏ¿© Áß¿äÇÑ ¿ªÇÒÀ» Çß½À´Ï´Ù.

Áö¿ªº° ºÐ¼®

Áö¸®ÀûÀ¸·Î 2024³â ºÏ¹Ì Áö¿ªÀº ³ôÀº ´ç´¢º´ À¯º´·ü, ¼±Áø ÀÇ·á ÀÎÇÁ¶ó ¹× ȯÀÚ ÀνĿ¡ ÈûÀÔ¾î ¸ÅÃâ Ãø¸é¿¡¼­ ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾Æ ÅÂÆò¾ç Áö¿ªÀº 2025³âºÎÅÍ 2033³â±îÁö °¡Àå ³ôÀº ¿¬Æò±Õ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àεµ¿Í Áß±¹°ú °°Àº ±¹°¡¿¡¼­ ±ÞÁõÇÏ´Â ´ç´¢º´ Àα¸¿Í ÀÇ·áºñ ÁöÃâ Áõ°¡, »õ·Î¿î Áø´Ü ½Ã¼³°ú °°Àº ¿äÀÎÀÌ ÀÌ·¯ÇÑ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¼º¼÷ÇÑ ÀÇ·á ½Ã½ºÅÛÀ» °®Ãá À¯·´Àº °è¼ÓÇØ¼­ Áß¿äÇÑ ±â¿©¸¦ ÇÒ °ÍÀ̸ç, ¶óƾ¾Æ¸Þ¸®Ä«¿Í ¾ÆÇÁ¸®Ä«´Â ÀÇ·á Á¢±Ù¼º ¹× °æÁ¦¼º°ú °ü·ÃµÈ °úÁ¦°¡ ÀÖÁö¸¸ ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀÔ´Ï

°æÀï µ¿Çâ

½ÃÀå °æÀï ±¸µµÀº Ç×»ó ¿ªµ¿ÀûÀÔ´Ï´Ù. 2024 ³â¿¡´Â Abbott Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, ARKRAY, Inc., ÁÖ¿ä EKF Diagnostics Holdings ±×¸®°í ¸é¿ª ÃøÁ¤ ¼Ö·ç¼ÇÀ» ¹«±â¿¡ ¿ìÀ§¸¦ Â÷ÁöÇÕ´Ï´Ù. À̵éÀÇ Àü·«Àº R&D, Áö¸®Àû È®Àå, Áø´Ü ¹× ¿¬±¸ ½ÇÇè½Ç°úÀÇ ÆÄÆ®³Ê½Ê ±¸Ãà¿¡ ÁßÁ¡À» µÎ¾ú½À´Ï´Ù. 2025³âºÎÅÍ 2033³â±îÁö ¿¹ÃøÇÑ ¹Ù¿Í °°ÀÌ, ÀÌ °Å´ë ±â¾÷µéÀº AI ÅëÇÕ ¹× ÀÚµ¿È­¿¡ ´õ ±íÀÌ ÆÄ°íµé¾î ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ ³ÐÈ÷°í ½Å¼ÓÇϰí È®Àå °¡´ÉÇϸç Á¤È®ÇÑ HbA1c °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺À» ÇØ°áÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

  • ºÐ¼® ³»¿ë
    • ºÐ¼®ÀÇ ¸ñÀû
    • ´ë»óÀÚ
    • ÁÖ¿ä Á¦°ø ³»¿ë
  • ½ÃÀå ¼¼ºÐÈ­
  • ºÐ¼® ¹æ¹ý
    • 1´Ü°è : 2Â÷ Á¶»ç
    • 2´Ü°è : 1Â÷ Á¶»ç
    • 3´Ü°è : Áö½ÄÀÎ ¸®ºä
    • ÀüÁ¦Á¶°Ç
    • äÅÃÇÑ Á¢±Ù

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : °æÀï ºÐ¼®

  • ÁÖ¿ä º¥´õÀÇ ½ÃÀå Æ÷Áö¼Å´×
  • º¥´õ°¡ äÅÃÇÑ Àü·«
  • ÁÖ¿ä »ê¾÷ Àü·«

Á¦4Àå HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ¸ÅÅ©·Î ºÐ¼® ¹× ½ÃÀå ¿ªÇÐ

  • ¼Ò°³
  • ¼¼°èÀÇ HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå(±Ý¾× ±âÁØ, 2023-2033³â)
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÁÖ¿ä °úÁ¦
    • ÁÖ¿ä ±âȸ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®
  • See-Saw ºÐ¼®
  • Porter's Five Forces ¸ðµ¨
    • °ø±ÞÀÚÀÇ Èû
    • ¹ÙÀ̾îÀÇ Èû
    • ´ëüǰÀÇ À§Çù
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû »óȲ
    • °æÁ¦Àû »óȲ
    • ±â¼úÀû »óȲ
    • ¹ýÀû »óȲ
    • »çȸÀû »óȲ

Á¦5Àå HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ±â¼úº°(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ¼ºÀå ¹× ¼öÀÍ ºÐ¼® : 2024³â vs 2033³â
  • ½ÃÀå ¼¼ºÐÈ­
    • À̿ ±³È¯ °í¼Ó ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ(HPLC)
    • ¸é¿ª ÃøÁ¤
    • ºØ»ê ģȭ¼º Å©·Î¸¶Åä±×·¡ÇÇ
    • Á÷Á¢ È¿¼Ò ºÐ¼®
    • ±âŸ

Á¦6Àå HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ¼ºÀå ¹× ¼öÀÍ ºÐ¼® : 2024³â vs 2033³â
  • ½ÃÀå ¼¼ºÐÈ­
    • Áø´Ü ½ÇÇè½Ç
    • º´¿ø³» °Ë»ç½Ç
    • ±âŸ(¿¬±¸±â°ü µî)

Á¦7Àå ºÏ¹ÌÀÇ HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ±â¼úº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ±âŸ ºÏ¹Ì

Á¦8Àå À¯·´ÀÇ HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ±â¼úº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • ¿µ±¹ ¹× EU
      • ¿µ±¹
      • µ¶ÀÏ
      • ½ºÆäÀÎ
      • ÀÌÅ»¸®¾Æ
      • ÇÁ¶û½º
      • ±âŸ À¯·´

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ±â¼úº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ±â¼úº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ±â¼úº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2023-2033³â)
  • HbA1c ½ÇÇè½Ç °Ë»ç ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿, ¾ÆÇÁ¸®Ä«

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
  • Ortho Clinical Diagnostics
  • ARKRAY Inc.
  • EKF Diagnostics Holdings plc
  • Meril Life Science Pvt. Ltd.
  • ±âŸ
HBR 25.02.25

In the realm of healthcare diagnostics, HbA1c laboratory testing holds a pivotal role, particularly in the context of diabetes management and monitoring. HbA1c tests provide an average blood glucose level over a period of three months, offering clinicians valuable insight into a patient's glycemic control. HbA1c laboratory testing market is estimated to grow at a CAGR of 5.5% from 2025 to 2033, driven by influenced by a myriad of factors ranging from global health trends to rapid technological evolution, influenced by technological advancements.

Driver - The Rising Global Prevalence of Diabetes

With diabetes becoming a significant public health concern worldwide, the demand for effective monitoring tools, including HbA1c laboratory tests, has witnessed a remarkable surge. Evidences highlight the alarming increase in diabetes incidence; for instance, the World Health Organization (WHO) had reported in the past decade about a steady rise in diabetes cases globally, signifying the sheer magnitude and urgency of this health predicament. In line with this, HbA1c tests have become indispensable in medical practice. Regular HbA1c testing allows for timely intervention, adjustment of medication regimens, and has been linked to better patient outcomes by aiding in the prevention of diabetes-related complications such as neuropathy, nephropathy, and retinopathy.

Opportunity - Integration of AI and Machine Learning in Diagnostics

Technological advancements in the realm of artificial intelligence (AI) and machine learning (ML) are opening new horizons for the HbA1c laboratory testing market. There's growing interest in utilizing AI algorithms to predict diabetes progression and related complications based on HbA1c results and other patient data. For example, several healthcare technology startups and established diagnostic labs are exploring ways to integrate AI-driven predictive analytics to offer more actionable insights from HbA1c test results. This not only augments the clinical utility of the test but also adds a layer of preventive care, assisting clinicians in proactive patient management.

Restraint - High Cost of Testing and Limited Accessibility in Low-Income Regions

Despite the undeniable importance of HbA1c tests, the cost remains a considerable barrier for many. In several regions, especially in low-to-middle income countries, the expense associated with regular HbA1c testing can be prohibitive. Moreover, some insurance policies do not cover HbA1c testing, adding to the out-of-pocket costs for patients. Additionally, the requisite infrastructure, including advanced laboratories and skilled technicians, might not be universally available, further restricting test accessibility. Such disparities in healthcare infrastructure were evident in a report by the International Diabetes Federation, which highlighted stark contrasts in diabetes care access between developed and developing nations.

Challenge - Variability and Standardization Concerns

One of the more pressing challenges in the HbA1c testing arena is the potential variability in test results. Different laboratories might use diverse testing methodologies, potentially leading to slight variances in outcomes. This poses a challenge, especially when patients switch healthcare providers or when clinicians rely on results from multiple labs. The American Diabetes Association has previously highlighted concerns regarding the standardization of HbA1c tests and has emphasized the need for globally consistent testing protocols to ensure uniformity and reliability.

Technology Insights

In 2024, the technologies that dominated the HbA1c laboratory testing market could be segregated into multiple categories. Ion Exchange High-Performance Liquid Chromatography (HPLC) emerged as the highest revenue-generating technology, attributed to its precision, repeatability, and robustness. Clinicians globally favored it for its accuracy in detecting even minor variances in HbA1c levels. However, Immunoassay showed the highest CAGR, mainly because of its rapid testing capabilities and its scalability for mass screenings, crucial for populous regions like South Asia. Boronate Affinity Chromatography and Direct Enzymatic Assay, although less prevalent, provided niche solutions in specific clinical scenarios. Other technologies complemented the market, catering to specialized needs or serving regions with specific diagnostic preferences.

End-User Insights

Diagnostic Laboratories in 2024 were the major contributors to the market's revenue. Their vast network, availability, and specialization in HbA1c testing made them the primary choice for many healthcare providers. On the other hand, Hospital-based Laboratories, though generating substantial revenue, were marked with the highest CAGR. This trend could be attributed to the rising in-patient diabetic population and the convenience of in-hospital testing facilities, ensuring prompt intervention. Other entities like Research Laboratories also played their part, especially in the context of clinical research and studies.

Regional Insights

Geographically, North America, in 2024, dominated the market in terms of revenue, backed by a high prevalence of diabetes, advanced healthcare infrastructure, and patient awareness. However, the Asia-Pacific region is expected to display the highest CAGR from 2025 to 2033. Factors such as burgeoning diabetic populations in countries like India and China, coupled with increasing healthcare expenditure and emerging diagnostic facilities, will fuel this growth. Europe, with its mature healthcare systems, will continue to be a significant contributor, while Latin America and Africa will present potential growth opportunities, albeit with challenges related to healthcare access and affordability.

Competitive Trends

The competitive landscape of the HbA1c Laboratory Testing market has always been dynamic. In 2024, key players like Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, ARKRAY, Inc., EKF Diagnostics Holdings plc, Meril Life Science Pvt. Ltd. dominated, leveraging their advanced HPLC and Immunoassay solutions. Their strategies focused on R&D, geographical expansion, and forging partnerships with diagnostic and research labs. As we forecast from 2025 to 2033, it's anticipated that these giants will delve deeper into AI integration and automation, broadening their footprints in emerging markets, and addressing the need for rapid, scalable, and accurate HbA1c testing solutions.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of HbA1c Laboratory Testing market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the HbA1c Laboratory Testing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
  • Technology
    • Ion Exchange High Performance Liquid Chromatography (HPLC)
    • Immunoassay
    • Boronate Affinity Chromatography
    • Direct Enzymatic Assay
    • Others
  • End-user
    • Diagnostic Laboratories
    • Hospital-based Laboratories
    • Others (Research Laboratories, etc.)
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of HbA1c Laboratory Testing market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the HbA1c Laboratory Testing market?
  • Which is the largest regional market for HbA1c Laboratory Testing market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving HbA1c Laboratory Testing market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the HbA1c Laboratory Testing market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global HbA1c Laboratory Testing Market
  • 2.2. Global HbA1c Laboratory Testing Market, By Technology, 2024 (US$ Million)
  • 2.3. Global HbA1c Laboratory Testing Market, By End-user, 2024 (US$ Million)
  • 2.4. Global HbA1c Laboratory Testing Market, By Geography, 2024 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2024

3. HbA1c Laboratory Testing Market: Competitive Analysis

  • 3.1. Market Positioning of Key HbA1c Laboratory Testing Market Vendors
  • 3.2. Strategies Adopted by HbA1c Laboratory Testing Market Vendors
  • 3.3. Key Industry Strategies

4. HbA1c Laboratory Testing Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global HbA1c Laboratory Testing Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Ion Exchange High Performance Liquid Chromatography (HPLC)
    • 5.3.2. Immunoassay
    • 5.3.3. Boronate Affinity Chromatography
    • 5.3.4. Direct Enzymatic Assay
    • 5.3.5. Others

6. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Diagnostic Laboratories
    • 6.3.2. Hospital-based Laboratories
    • 6.3.3. Others (Research Laboratories, etc.)

7. North America HbA1c Laboratory Testing Market, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
  • 7.3. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
  • 7.4.HbA1c Laboratory Testing Market: By Region, 2023-2033, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 7.4.1.1.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 7.4.1.2.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 7.4.1.3.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)

8. UK and European Union HbA1c Laboratory Testing Market, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
  • 8.3. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
  • 8.4.HbA1c Laboratory Testing Market: By Region, 2023-2033, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 8.4.1.1.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 8.4.1.2.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 8.4.1.3.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 8.4.1.4.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 8.4.1.5.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 8.4.1.6.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)

9. Asia Pacific HbA1c Laboratory Testing Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
  • 9.3. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
  • 9.4.HbA1c Laboratory Testing Market: By Region, 2023-2033, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 9.4.1.1.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 9.4.1.2.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 9.4.1.3.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 9.4.1.4.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 9.4.1.5.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 9.4.1.6.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)

10. Latin America HbA1c Laboratory Testing Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
  • 10.3. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
  • 10.4.HbA1c Laboratory Testing Market: By Region, 2023-2033, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 10.4.1.1.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 10.4.1.2.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 10.4.1.3.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)

11. Middle East and Africa HbA1c Laboratory Testing Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
  • 11.3. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
  • 11.4.HbA1c Laboratory Testing Market: By Region, 2023-2033, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 11.4.1.1.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 11.4.1.2.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. HbA1c Laboratory Testing Market: By Technology, 2023-2033, USD (Million)
        • 11.4.1.3.2. HbA1c Laboratory Testing Market: By End-user, 2023-2033, USD (Million)

12. Company Profile

  • 12.1. Abbott Laboratories
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Bio-Rad Laboratories, Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. F. Hoffmann-La Roche Ltd.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Danaher Corporation
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Siemens Healthcare GmbH
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Thermo Fisher Scientific, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Ortho Clinical Diagnostics
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. ARKRAY, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. EKF Diagnostics Holdings plc
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Meril Life Science Pvt. Ltd.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Others
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦